MoxiGel

**MoxiGel** is an investigational ophthalmic combination product developed by EyeGate Pharmaceuticals and subsequently associated with its successor, Kiora Pharmaceuticals, for bacterial conjunctivitis. It combines EyeGate's Ocular Bandage Gel, a modified hyaluronic-acid-based ocular-surface protective gel intended to support corneal re-epithelialization and ocular-surface integrity, with an approved antibacterial agent whose identity has not been publicly disclosed. EyeGate reported positive FDA pre-IND feedback in August 2020 and planned an IND submission after completing preclinical work. ([kiorapharma.com](https://kiorapharma.com/eyegate-pharma-confirms-path-forward-with-fda-to-develop-combination-product/))

Other names

MoxiGel